AndhraNews.net
Home » Business News » 2014 » November » November 7, 2014

Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014


November 7, 2014 - Columbia, Md And Toronto, ON

Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be broadcast on both the BNN and the Fox Business News Network by Taylor Thoen, Executive Producer of BTV-Business TV. This broadcast will be a segment of the episode that will feature Gilead Sciences, Cynapsus Therapeutics, and biOasis Technologies Inc.

This episode will be aired:

U.S. National: Fox Business News Saturday, Nov 8 @ 5:30pm EST; America One - Saturday, Nov 8 @ 10am EST; Biz Television Network - Thurs. Nov 13 @ 10:00pm & 1:00am EST; and Sunday Nov 16 @ 12:30pm, 9:00pm & 12:00am EST.

BTV BROADCAST TIMES: CANADA: BNN - Sunday, Nov 9 @ 9:30am & 8:00pm EST; Bell Express Vu - Sunday, Nov 9 @ 9:30am & 8:00pm EST

In addition to being aired on the above dates and times, the excerpt will be available on the BTV website and on the following link: http://video.b-tv.com/previews/SJuWLE28-oN97cVjN

About Medifocus, Inc.

Medifocus owns two fully developed technology platforms with comprehensive United States and international patent protection: (i) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The United States Food and Drugs Administration (FDA) approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. Medifocus' APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, has received approval from the FDA and Health Canada to conduct the pivotal Phase III clinical trials. Medifocus believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers.

Please visit www.medifocusinc.com, www.prolieve.com and http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.

Forward-Looking Statements and Information

This news release contains "forward-looking statements" and "forward-looking information", which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect the structure and the proceeds of the Offering and the expected use of the proceeds. Forward-looking statements are frequently characterized by words such as "plan," "expect," "project," "intend," "believe," "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, Medifocus disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Medifocus Contact:
John Mon
COO
Medifocus, Inc.
Tel: 410-290-5734
JohnMon@medifocusinc.com

MarketWire

Comment on this story

Share